Spotlighting Alternative Clinical Trial Designs to Improve Evaluation of RAS-Targeting Therapies Leading to Accelerated Approvals
- How to create alternative clinical trial designs to better assess efficacy and reduce traditional barriers
- Uncovering lessons from past trials and using them to inform future clinical trials for KRAS inhibitorsÂ
- Highlighting the importance of considering additional mutations beyond KRAS to predict treatment responses